Geoff Meyerson
Vorstandsvorsitzender bei Locust Walk Securities LLC
Aktive Positionen von Geoff Meyerson
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Locust Walk Securities LLC
Locust Walk Securities LLC Investment Banks/BrokersFinance Locust Walk Securities LLC is a securities brokerage firm headquartered in Boston, Massachusetts. The firm was founded by Geoffrey Meyerson and Joseph Mohr in 2011 and they are a subsidiary of Locust Walk Partners LLC. Locust Walk Securities serves as the broker-dealer for all Locust Walk engagements – enabling them to execute a wider range of securities-related transactions for their clients, which includes mergers and acquisitions, private placements and mezzanine financings, and partnerships involving equity investments. | Vorstandsvorsitzender | 01.01.2011 | - |
Gründer | 01.01.2011 | - | |
Locust Walk Partners LLC
Locust Walk Partners LLC Miscellaneous Commercial ServicesCommercial Services Locust Walk Partners LLC provides commercial supporting and advisory services. The firm involves in securities-related transactions for clients, including mergers and acquisitions, private placements & mezzanine financings and partnerships involving equity investments. The company was founded by Geoff Meyerson and Joseph Mohr in 2008 and is headquartered in Boston, MA. | Vorstandsvorsitzender | 01.12.2008 | - |
Gründer | 01.12.2008 | - | |
Corporate Officer/Principal | 01.12.2008 | - |
Karriereverlauf von Geoff Meyerson
Ehemalige bekannte Positionen von Geoff Meyerson
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
AI Proteins, Inc.
AI Proteins, Inc. Pharmaceuticals: MajorHealth Technology AI Proteins, Inc. is a biotech company based in Andover, MA. AI Proteins is focused on re-imagining protein therapeutics by designing entirely new proteins using an AI-based approach and a high-throughput drug discovery platform. The company's platform enables the development of inexpensive, durable, and highly specific proteins optimized for specific therapeutic applications. These proteins have the potential for oral delivery and can dramatically accelerate the development of lead therapeutic candidates ready for IND-enabling studies. The company was founded by Marc A. Cohen and Christopher Bahl. Noah D. Beerman has been the CEO of the company since 2023. | Direktor/Vorstandsmitglied | - | - |
Statistik
International
Vereinigte Staaten | 4 |
Operativ
Chief Executive Officer | 2 |
Founder | 2 |
Corporate Officer/Principal | 1 |
Sektoral
Finance | 2 |
Commercial Services | 2 |
Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 3 |
---|---|
Locust Walk Securities LLC
Locust Walk Securities LLC Investment Banks/BrokersFinance Locust Walk Securities LLC is a securities brokerage firm headquartered in Boston, Massachusetts. The firm was founded by Geoffrey Meyerson and Joseph Mohr in 2011 and they are a subsidiary of Locust Walk Partners LLC. Locust Walk Securities serves as the broker-dealer for all Locust Walk engagements – enabling them to execute a wider range of securities-related transactions for their clients, which includes mergers and acquisitions, private placements and mezzanine financings, and partnerships involving equity investments. | Finance |
Locust Walk Partners LLC
Locust Walk Partners LLC Miscellaneous Commercial ServicesCommercial Services Locust Walk Partners LLC provides commercial supporting and advisory services. The firm involves in securities-related transactions for clients, including mergers and acquisitions, private placements & mezzanine financings and partnerships involving equity investments. The company was founded by Geoff Meyerson and Joseph Mohr in 2008 and is headquartered in Boston, MA. | Commercial Services |
AI Proteins, Inc.
AI Proteins, Inc. Pharmaceuticals: MajorHealth Technology AI Proteins, Inc. is a biotech company based in Andover, MA. AI Proteins is focused on re-imagining protein therapeutics by designing entirely new proteins using an AI-based approach and a high-throughput drug discovery platform. The company's platform enables the development of inexpensive, durable, and highly specific proteins optimized for specific therapeutic applications. These proteins have the potential for oral delivery and can dramatically accelerate the development of lead therapeutic candidates ready for IND-enabling studies. The company was founded by Marc A. Cohen and Christopher Bahl. Noah D. Beerman has been the CEO of the company since 2023. | Health Technology |
- Börse
- Insiders
- Geoff Meyerson
- Erfahrung